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Abstract: Diabetes is a chronic disease characterized by inadequate insulin secretion with 
resulting hyperglycemia. Diabetes complications include both microvascular and macrovascular 
disease, both of which are affected by optimal diabetes control. Many individuals with diabetes 
rely on subcutaneous insulin administration by injection or continuous infusion to control 
glucose levels. Novel routes of insulin administration are an area of interest in the diabetes 
field, given that insulin injection therapy is burdensome for many patients. This review will 
discuss pulmonary delivery of insulin via inhalation. The safety of inhaled insulin as well as 
the efficacy in comparison to subcutaneous insulin in the various populations with diabetes are 
covered. In addition, the experience and pitfalls that face the development and marketing of 
inhaled insulin are discussed.
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Introduction
Diabetes is a class of diseases characterized by elevated blood sugar in the face of 
inadequate insulin production or insulin action. The disease affects approximately 
23.6 million Americans (8% of the population), and fully one-third of those individuals 
are unaware that they have the disease.1 There are two broad categories of diabetes – type 1 
(T1DM) and type 2 diabetes (T2DM). Individuals with T1DM are dependent on insulin 
for survival and rely on subcutaneous administration by injection or continuous infusion. 
Patients with T2DM may control their disease for a time with lifestyle intervention or 
oral therapies. However, those who fail these strategies will require insulin to achieve 
adequate disease control. Delivery of insulin via inhalation is a potential alternative 
to subcutaneous insulin in the management of diabetes. This review will discuss the 
rationale for development of pulmonary delivered versions of insulin as well as discuss 
the role that inhaled insulin may play in improving long-term diabetes care.
Rationale for intensified diabetes care
Associations between hyperglycemia and the long-term complications of diabetes have 
been demonstrated both in animal models and human studies. Elevated glucose levels 
lead to significant vascular endothelial cell dysfunction, contributing to morbidities 
associated with the disease.2 Individuals with diabetes are at risk for both microvascular 
disease including nephropathy, retinopathy, and neuropathy and macrovascular disease 
including both fatal and nonfatal myocardial infarction and stroke. Epidemiologic 
studies have demonstrated a correlation between diabetes and cardiovascular disease. Vascular Health and Risk Management 2010:6 48
Mastrandrea Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The diagnosis of T2DM increases the risk of coronary heart 
disease by a factor of 2- to 4-fold,3 while those with T1DM 
have about a 10-fold increase in cardiovascular disease com-
pared to age-matched individuals without diabetes.4,5 Large 
prospective trials, such as the Diabetes Control and Com-
plications Trial (DCCT, T1DM)6 and the United Kingdom 
Prospective Diabetes Study (UKPDS, T2DM),7 have dem-
onstrated that improving metabolic control, as measured by 
mean glycosylated hemoglobin (HbA1c), decreases the risk 
of microvascular complications. Declines in HbA1c correlate 
with reductions in both the development and progression of 
diabetic retinopathy, nephropathy, and neuropathy, indicating 
that addressing hyperglycemia is relevant even in those with 
established complications. These large trials did not show 
declines in macrovascular disease with improved blood sugar 
control. However, in the Epidemiology of Diabetes Interven-
tions and Complications Trial (EDIC), a follow-up of the 
DCCT, patients who had received intensified therapy for a 
period of 6.5 years had a 42% decrease in the risk of a first 
cardiovascular event compared to the conventionally treated 
group.6 More recent studies have called into question the goal 
of striving for near-normal glycemic control (HbA1c  6%) 
in the T2DM population because of increased risk of cardio-
vascular death. Current recommendations in diabetes care are 
to aim for as close to euglycemia as possible.
While intensive therapy is recognized as a means to 
improve long-term outcomes for patients with diabetes, fewer 
than 40% of patients achieve the glycemic targets set forth 
by the American Diabetes Association (ADA) and American 
Association of Clinical Endocrinologists (AACE). Barriers to 
achieving these goals are multi-factorial and include failure of 
patients to accept intensified therapies and inability of current 
regimens to mimic physiologic insulin delivery.
Intensive therapy in T1DM involves multiple daily sub-
cutaneous injections of insulin (3 to 5 per day) usually with 
long-acting insulin as basal insulin and short-acting insulin 
administered just prior to meals. Alternatively, continuous 
subcutaneous insulin infusion (CSII) pumps can be used. 
For individuals with T2DM, initial management includes 
lifestyle interventions such as diet and exercise. However, 
most patients will eventually require oral therapies that 
stimulate pancreatic β-cell insulin secretion (secretagogues) 
or improve insulin sensitivity (biguanides or thiazolidinedio-
nes). If glycemic goals are not met, insulin therapy must 
be initiated. For patients with diabetes, either intensifying 
(T1DM) or adding (T2DM) insulin therapy can be challeng-
ing. Patients often resist transitioning to insulin injections out 
of fear and concern about the skill sets needed to correlate 
carbohydrate intake with insulin administration.8 Because of 
these concerns, intensification of insulin therapy to improve 
metabolic control is often delayed, and adherence to injection 
regimens may be suboptimal.
Secretion of insulin in response to carbohydrate intake is 
tightly regulated.9 Insulin is released into the portal venous 
system to exert effects at the liver initially, suppressing 
glycogenolysis and gluconeogenisis before acting peripher-
ally to stimulate glucose uptake and inhibit lipolyis.10 Current 
strategies of subcutaneous insulin administration do not mimic 
this first-pass effect of insulin on hepatic glucose control. 
Thus, particularly for fasting/basal glucose control, subcutane-
ous therapy fails to restore intra-portal insulin concentrations 
resulting in inappropriate hepatic glucose output. Attempts 
to address this therapeutic concern by increasing doses of 
basal insulin may place the patient at risk for hypoglycemia, 
particularly in the fasting state. While available insulin 
analogs provide improved coverage of meal-time glucose 
excursions, timing of insulin administration and careful atten-
tion to matching carbohydrate ingestion with insulin dose is 
paramount to limit post-prandial hyperglycemia.
Therapies aimed at addressing these concerns include oral 
insulin (intestinal absorption and buccal mucosal absorption), 
implantable peritoneal insulin pumps, and inhaled insulin. 
While enteral insulin therapy is limited by enzymatic deg-
radation, there are ongoing trials to assess the feasibility of 
oral spray insulin in the treatment of T1DM compared to 
twice daily insulin injections (www.clinicaltrials.gov iden-
tifier NCT00668850).11 A recent study demonstrated that 
compared to traditional CSII, patients using the implantable 
peritoneal insulin pump had reduced HbA1c with more time 
spent in the euglyemic range and less time in the hyperglyce-
mic range. However, this option may be limited by cost and 
does carry the risk of peritoneal infections and implantation 
site complications.12 Finally, pulmonary delivery of insulin, 
which was first tested in 1924,13,14 has been an area of active 
investigation and development.
The lung as a vehicle  
for drug adminstration
Pulmonary delivery of drugs is used extensively in the 
treatment of respiratory diseases such as asthma, chronic 
obstructive pulmonary disease (COPD), and cystic fibrosis. 
Treatment goals for these disorders are to deliver drugs 
locally to affect bronchospasm (β-agonists), inflammation 
(inhaled steroids), and local bacterial infection (antibiot-
ics), while limiting systemic effects. The distal lung pro-
vides a large surface area (145 m2) with a thin (0.2 µM) Vascular Health and Risk Management 2010:6 49
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alveolar epithelium allowing for absorption of particles into 
the bloodstream for systemic action.15 Factors which influence 
the distribution of drugs to the distal lung include particle 
size, particle speed, and ventilatory parameters. In order 
for particles to be deposited in the alveolar space, their size 
should be between 1 and 3 µM; smaller particles are exhaled 
and particles 5 µM are deposited in the upper airways or 
swallowed.16 Patient cooperation and appropriate ventilator 
technique are important to ensure reproducible delivery 
of drug to the deep lung. Inhalers that allow for release of 
the insulin particles at the start of a deep, slow inhalation 
provide the best penetration to the alveolar space.17,18 Rapid 
shallow inhalations lead to significant losses of the drug in 
the oropharynx and upper airways. Thus, ability to perform 
appropriate breathing maneuvers plays an important role in 
maximizing the effectiveness of inhaled insulin therapy.
Development of inhaled insulin
Shortly after Banting and Best discovered insulin in the early 
1920s,19 the first studies using inhaled insulin were per-
formed. In these studies, it was reported that blood glucose 
decreased in response to inhalation of insulin.14,20 In 1987, 
it was demonstrated that nebulized human insulin provided 
blood sugar control comparable to subcutaneous insulin in 
6 children with T1DM.21 However, it was recognized that 
the bioavailability of inhaled insulin was significantly lower 
than that of subcutaneous preparations. Consequently, it was 
not until the development of improved delivery devices and 
understanding of particle pharmacology that inhaled insulin 
became ready for clinical study.
Inhaled insulin devices
Devices capable of delivering particulate insulin to the 
alveolar space have been developed and studied in a variety 
of clinical protocols. The ideal device should not only 
deliver insulin in a consistent fashion in order to achieve 
optimal glycemic control, but also should be convenient for 
patients – both portable and user-friendly. Over the course 
of the last 20 years, several companies have worked to 
develop inhaled insulin systems for patient use. The systems 
differ in the formulation of the inhaled insulin – liquid vs 
lyophilized powder – and the delivery device with respect to 
size, mechanism of insulin release, and regulation of insulin 
administration (mechanical vs electronic). The bioavailability 
of inhaled insulin for each of the devices varies, but is in the 
range of 10% to 46%, with much of the drug being lost within 
the device or in the oropharynx or upper airways.22 Table 1 
summarizes the features of inhaled insulin delivery systems 
that have been studied most extensively.
Exubera® was developed through a collaboration between 
Nektar Therapeutics and Pfizer and, in 2006, was approved 
by the Food and Drug Association (FDA) and the European 
Medicines Agency (EMEA) for treatment of both T1DM and 
T2DM. The insulin delivered by this device is a dry powder 
formulation packaged in blister packets containing 1 mg or 
3 mg of regular human insulin. The unit doses are delivered 
via a mechanical inhaler and are equivalent to 3 units and 
8 units of subcutaneously delivered short-acting insulin, 
respectively. Much of the medical literature describing the 
pharmacokinetics, glucodynamics, and safety profiles of 
inhaled insulin was obtained from studies using Exubera®. 
However, in October 2007, Pfizer announced that it would 
no longer be selling Exubera® secondary to poor sales and 
acceptance.
The AERx insulin diabetes management system (AERx® 
iDMS) was developed by both Aradigm Corporation and 
Novo Nordisk. This system creates an aerosol of insulin 
droplets from a liquid insulin preparation. The device has 





Insulin equivalentsa Inhaler 
device
Method of  
inhalation
Device Sizeb Device benefits Current status
exubera® Dry powder,  
blisters
1 mg = 3 U  
3 mg = 8 U
Mechanical User dependent 20 cm × 4 cm Collapsible FDA-approved 
off-market
AeRx iDMS® Liquid insulin,  
blisters
1 AeRx unit = 1 U electronic Guided system 8 cm × 4 cm Download capability No further  
development
AiR® Dry powder,  
capsules
6 mg = 2 U  
9 mg = 6 U
Mechanical Breath actuated 7 cm × 2 cm Small device size No further  
development
Technosphere® Dry powder  
microspheres,  
cartridges
6 TU = 1.56 U  
12 TU = 3.12 U  
24 TU = 6.24 U
Mechanical User dependent 10 cm × 5 cm Placebo formulation Phase 3 trials  
FDA – new drug  
application
aCompared to regular insulin; bapproximate size.
Abbreviation: TU, technosphere units.Vascular Health and Risk Management 2010:6 50
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electronic controls that guide the user to inhale the insulin 
in a reproducible fashion. In addition, the device offers the 
capability to download dosing, use frequency, and inhala-
tion patterns to aid the prescriber and patient in monitoring 
adherence and treatment goals. Although the AERx® system 
was in phase III trials, Novo Nordisk elected to discontinue 
further study with this system given the experience of Pfizer 
with Exubera®.
AIR® insulin system, developed in conjunction with Eli 
Lilly and Co. and Alkermes Inc. uses a dry powder insulin 
with a mechanical inhaler. The inhaled particles are signifi-
cantly larger (5 to 30 µM), yet less dense than those of other 
systems, and are delivered efficiently to the alveolar space. 
While this system has been through extensive phase III test-
ing, Eli Lilly and partners are not pursuing development of 
this product at present.
The Technosphere® system combines a dry powder recom-
binant human insulin (Mannkind Corp.) with the MedTone® 
inhaler (Pharmaceutical Discovery Corp.). This system is 
currently in phase III trials and is unique in that the partners 
have developed a placebo formulation for inhalation, allow-
ing for design of double-blind, placebo controlled studies in 
patients with T2DM.23 Technosphere® compares favorably 
to regular insulin administrated subcutaneously in control-
ling postprandial hyperglycemia, suggesting that this formu-
lation may provide improved blood sugar control.24
While there are other inhaled insulin devices/systems 
that have been developed, much of the investigation in this 
area has been halted. A review of www.clinicaltrials.gov 
using inhaled insulin as a key word revealed 75 trials, 20 of 
which were terminated before projected completion dates. 
Only 5 trials of inhaled insulin are listed as either actively 
recruiting or not yet recruiting, 4 of which are investigating 
Technosphere® insulin.25 Mannkind has filed a new drug 
application with the FDA; it remains to be seen whether this 
application will be approved.26
Pharmacology of inhaled insulin
Discussion of the pharmacology of inhaled insulin involves 
both the study of pharmacokinetics – measurement of serum 
insulin levels following administration of the drug – and 
pharmacodynamics – measurement of onset and dura-
tion of hypoglycemic effect. Most of the inhaled insulin 
devices are designed to be used in conjunction with carbo-
hydrate consumption, targeting control of prandial glucose 
excursions. The ideal system would closely mimic β-cell 
secretion of insulin with rapid onset of action followed by 
sustained activity over a period of 2–3 hours to control rising 
glucose concentrations while limiting delayed hypoglycemic 
effects. The majority of studies compare different inhaled 
insulin delivery systems to regular insulin administered 
subcutaneously which has a peak effect on glycemia 
30–60 minutes after administration and duration of action 
up to four hours.
Pharmacokinetics of inhaled insulin
Studies to assess serum concentrations of insulin following 
inhalation have been performed in healthy volunteers as well 
individuals with both T1DM and T2DM. A summary of the 
pharmokinetic parameters for various inhaled insulin devices 
is provided by Patton et al.22 In a comparison of Exubera® 
and regular insulin in healthy nonsmoking males, the total 
insulin exposure was similar for inhaled insulin and regular 
insulin.27 However, the time to maximal insulin concentration 
(Cmax) was more rapid for inhaled insulin vs regular insulin 
(55 min vs 148 min). In an open-label 4-way crossover study 
in healthy volunteers comparing 3 different Technosphere® 
inhaled insulin doses and regular insulin, similar results were 
found – Cmax was 12 to 17 min for Technosphere insulin and 
134 min for regular insulin.28 Studies performed with the 
AERx® system in patients with T1DM also revealed there 
was a more rapid rise in serum insulin in the inhaled group vs 
regular insulin group.29 However, the intrasubject variabil-
ity with respect to total insulin exposure was ∼26% for the 
inhaled group, indicating that consistent inhalation tech-
niques could play a significant role in diabetes control. Rave 
et al compared Technosphere® insulin to regular insulin in 
16 patients with T2DM.24 Cmax was reached earlier (15 min vs 
120 min) and was 45% greater for inhaled insulin compared 
to regular insulin. In addition, while the total insulin exposure 
for inhaled insulin was comparable to that of subcutaneous 
insulin, the exposure time was shorter with inhaled insulin, 
suggesting that the risk of delayed hypoglycemia may be less 
with the inhaled insulin formulation.24
Glucodynamics of inhaled insulin
Glucodynamics is measured by determining the infusion 
rate of glucose necessary to maintain euglycemia following 
the administration of insulin. This parameter determines the 
hypoglycemic effect of therapy. In healthy males receiving 
inhaled insulin, rates of glucose infusion were higher in 
the first hour after dosing than in those receiving regular 
insulin by injection, correlating with the more rapid rise in 
serum insulin levels.27 This maximal effect on glycemia is 
comparable to short-acting insulin analogs. Total glucose 
consumption was comparable for bioequivalent doses of Vascular Health and Risk Management 2010:6 51
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inhaled vs regular insulin over the entire clamp period.27 In 
individuals with T1DM, the glucose infusion rate profile 
showed an early peak rate with inhaled insulin (AERx®) vs 
regular insulin with a similar glucose consumption.29 Rave 
et al performed mixed-meal tolerance tests in 16 individu-
als with T2DM and compared the ability of Technosphere® 
insulin and regular insulin to control postprandial glucose 
levels. Both maximal postprandial glucose excursion and 
total blood glucose area under the curve were significantly 
lower following use of inhaled insulin in this group, indicat-
ing that for similar insulin exposure, glycemic control was 
improved with inhaled insulin.24 The rapid onset of action 
coupled with the ability to exert an effect on glucose levels 
for several hours after administration, makes inhaled insulin 
a good candidate for control of meal-time glucose levels.
Bioavailability of inhaled insulin is limited by several fac-
tors including losses of the drug within the inhalation device, 
oropharynx, or upper airways, as well as adequate ventila-
tory maneuvers to deposit insulin to the lower airways.22 In 
studies using the AERx® device in individuals with T1DM, it 
was estimated that the system efficiency on a unit/kilogram 
basis was 13% as measured by glucodynamics compared to 
injected regular insulin.29 This indicates that more insulin is 
needed for inhalation therapy compared to injection, a factor 
which could play a role in risk of long-term side effects as 
well as cost of therapy.
Equivalence dosing of inhaled 
insulin
Pharmacokinetic and glucodynamic studies have been 
performed to determine the equivalence of each inhaled 
insulin formulation relative to subcutaneous insulin.30,31 
These results are summarized in Table 1. In order for 
patients to receive the appropriate amount of insulin to 
cover carbohydrate ingestion, they must perform a series 
of inhalations using the doses available for each delivery 
system. For example, a patient normally requiring 10 units 
of regular insulin could inhale either three 1 mg blisters 
(9 unit equivalents) or one 1 mg blister and one 3 mg blister 
(11 unit equivalents) of Exubera® to achieve a comparable 
insulin dose. A study was performed in healthy nonsmoking 
adults to determine whether different dose combinations of 
AIR® capsules were interchangeable.32 The pharmacokinetic 
and glucodynamic results demonstrated that combinations 
of different AIR® capsule dose strengths were equivalent. 
Thus, there is greater flexibility with insulin dosing as well 
as less glycemic variability when equivalent dose strengths 
are interchanged in this system.
Use of inhaled insulin  
in treatment of diabetes
Multiple studies have been performed in patients with both 
T1 and T2DM to assess the efficacy of inhaled insulin in 
controlling diabetes. Inhaled insulin has been compared to 
regular insulin or short-acting insulin analogs in patients 
with T1DM. Studies including individuals with T2DM have 
assessed the effect of inhaled insulin on diabetes control when 
added to oral therapy as well as in comparison to short-acting 
insulin. Outcome measures have included HbA1c, pulmonary 
function, weight gain, and patient satisfaction.33
Type 1 diabetes
Current strategies to control blood glucose levels in indi-
viduals with T1DM involve subcutaneous insulin injections 
given multiple times per day (2 to 5) or insulin pump therapy 
via CSII. In patients receiving injection therapy, they gen-
erally receive long-acting (basal) insulin 1 or 2 times/day 
and short-acting insulin with meals to cover post-prandial 
meal excursions. Multiple daily injection therapy places a 
burden on patients and is a significant barrier to optimizing 
adherence to diabetes regimens aimed at improving glycemic 
control. Inhaled insulin has the potential to replace short-
acting insulin analogs, eliminating as many as 4 injections 
per day.
Inhaled insulin administered before meals has been 
compared in a randomized controlled fashion to regimens 
using regular insulin preprandially and either NPH (twice 
daily) or ultralente (once daily). In studies performed using 
Exubera®, inhaled insulin was noninferior with respect to 
HbA1c changes, although 2-hour postprandial and fasting 
plasma glucose levels were lower in the groups receiving 
inhaled insulin.34,35 In a recent study reported by Garg et al 
385 individuals with T1DM were randomized to receive 
either inhaled insulin (AIR®) or regular/lispro insulin before 
meals with glargine serving as the basal insulin.36 After 
2 years of study, only 20% of study subjects reached a target 
HbA1c of  7%, and inhaled insulin was demonstrated to 
be inferior to preprandial subcutaneous insulin with respect 
to change in HbA1c. When individuals with T1DM were 
treated with glargine as basal insulin and randomized to 
either Technosphere® inhaled insulin or rapid acting insulin 
analog, both groups had comparable decreases in HbA1c at 
1 year; however, the inhaled insulin group had significantly 
lower fasting plasma glucose and 1 hour postprandial glu-
cose levels compared to those on subcutaneous insulin.37 
The discrepancies between the studies related to effects 
of inhaled insulin on HbA1c may be related either to the Vascular Health and Risk Management 2010:6 52
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inhaled insulin formulation itself or to the basal insulin 
used in each study.
Type 2 diabetes
Individuals with T2DM often have complicated medication 
regimens when the addition of insulin is considered. Patients 
may be taking several different classes of drugs in an effort 
to control blood sugars – oral hypoglycemic agents (sulfo-
nylureas or meglitinides) and insulin sensitizers (biguanides 
or thiazolidindiones). Rosenstock et al performed a trial in 
T2DM patients on dual oral agent therapy who continued to 
have poor glycemic control (HbA1c  8%). Patients were 
randomized to continued oral therapy, oral therapy plus 
Exubera®, or Exubera® alone. HbA1c improved by 1.4% 
(inhaled) and 1.9% (inhaled plus oral agents) compared to 
oral agents alone.38 This suggests that some patients may 
achieve adequate glycemic control on inhaled insulin alone, 
thereby simplifying their treatment regimen. In addition, 
individuals randomized to inhaled insulin plus oral agents had 
a greater likelihood of reaching glycemic targets compared 
to those on oral agents alone (32% vs 1%).38
As discussed above, Mannkind Corporation has devel-
oped a placebo based device for use in clinical trials as a com-
parator to Technosphere® inhaled insulin. This controls for the 
attention received by subjects within a study as well as the 
motivation factor ascribed to subjects who are randomized to 
inhaled insulin, in contrast to subcutaneous insulin, that may 
bias study outcomes. Individuals with T2DM suboptimally 
controlled on oral agents were randomized in a double-blind 
fashion to receive either placebo Technosphere® powder 
or Technosphere® insulin before meals.23 Use of inhaled 
insulin resulted in a significant decline in HbA1c compared 
to those using placebo, taking into consideration that HbA1c 
was mildly elevated in all subjects at baseline (8%, inhaled 
insulin group; 7.8% placebo group).
In a study of patients with T2DM on insulin therapy, 
subjects received either pre-meal Exubera® plus ultralente 
(subcutaneous) or twice daily injections of regular and 
NPH insulin.39 There was no difference in the reduction in 
HbA1c between the groups, although those randomized to 
inhaled insulin were more likely to achieve HbA1c  7% 
(odds ratio 2.27, 95% confidence interval 1.24 to 4.14). In a 
similar population of patients with T2DM, AERx® premeal 
inhaled insulin was compared to premeal subcutaneous 
regular insulin, both in combination with bedtime NPH 
insulin.40 After 12 weeks of therapy, there was no differ-
ence in HbA1c between the two groups, and both groups 
experienced a similar decline in HbA1c from baseline 
(–0.69% vs –0.77%; inhaled vs subcutaneous). A further 
study in individuals with poorly controlled T2DM receiving 
oral therapy plus basal glargine demonstrated that the addi-
tion of AIR® inhaled insulin to once-daily glargine resulted 
in a greater improvement in HbA1c (–0.97% vs –0.62%; 
inhaled + glargine vs glargine), even when glargine dose 
was titrated to optimize glycemic control.41 Individu-
als with T2DM initially randomized to either inhaled or 
subcutaneous insulin in a 12-week proof of concept study 
were offered the option of continuing inhaled insulin for 
1 year.30 In those who elected to continue inhaled insulin, 
the decrease in HbA1c (–0.78%) was sustained throughout 
the extension trial, indicating that the therapeutic effects on 
glycemic control are durable.42 It should be noted that, thus 
far, no clinical trial has demonstrated that inhaled insulin 
is superior to subcutaneous insulin for the goal of diabetes 
care – improved glycemic control.
Special populations
Smoking and inhaled insulin
It is estimated that 20% to 25% of individuals with dia-
betes are tobacco smokers.43 Smoking induces both acute 
and chronic effects on the pulmonary system, including 
vasoconstriction, changes in permeability, and remodel-
ing of the bronchioalveolar lining. Therefore, efforts have 
been made to address the effects that smoking has on the 
pharmacokinetics of inhaled insulin. Following administra-
tion of inhaled insulin, nondiabetic chronic smokers have 
a higher Cmax, greater absorption of insulin (AUC0–360), and 
shorter time to Cmax nonsmokers.44,45 These data suggest 
that individuals who smoke would be at higher risk for 
hypoglycemia when treated with inhaled insulin. Becker 
et al examined the effects of smoking cessation on pharma-
cokinetics of inhaled insulin.46 Within 1 week of smoking 
cessation, the Cmax and AUC0–360 after inhaled insulin had 
decreased significantly and approached that of nonsmokers. 
Resumption of smoking reversed the effects of smoking 
cessation, with both insulin exposure and glucose utiliza-
tion increasing. However, tobacco use is also associated 
with insulin-resistance,47 and Wise et al demonstrated that 
although nondiabetic smokers had a greater exposure to 
insulin following inhalation compared to nonsmokers, they 
did not have increased glucose utilization as measured by 
glucose infusion rates.44 Therefore, particularly in the T2DM 
population, the increase in alveolar permeability that leads 
to increased insulin absorption following inhalation may be 
counteracted by the effects of insulin resistance mediated 
both by the disease state and smoking.Vascular Health and Risk Management 2010:6 53
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In contrast to chronic smoking, individuals who are 
exposed to passive smoking have a different response 
to inhaled insulin. In healthy nonsmokers, exposure to 
cigarette smoke for 2 hours prior to insulin inhalation 
resulted in significantly lower insulin bioavailability and 
pharmacokinetic parameters.48 This is similar to the effect 
of acute cigarette smoking just prior to insulin inhalation 
by smokers, where the AUC0–360 is not increased.45 Thus, 
smoking, whether acute or chronic, passive or primary, 
impacts the pharmacokinetics of inhaled insulin, placing 
patients at risk for fluctuations in blood sugars with result-
ing suboptimal metabolic control.
When inhaled insulin was on the market, it was not 
approved for smokers or for those who had smoked within 
the previous 6 months. Given the fact that Pfizer and Nektar 
Pharmaceuticals announced an increase in lung cancer cases 
in former smokers involved in clinical trials of Exubera®, it 
is unlikely that any inhaled insulin that comes to market in 
the future will be approved for either smokers or previous 
smokers.49
Respiratory disease and inhaled 
insulin
Because both acute and chronic respiratory diseases have 
the potential to alter the pharmacodynamic effects of inhaled 
insulin, it is necessary to understand how illness and pul-
monary pathology influence inhaled insulin action. Acute 
respiratory illnesses are a common occurrence and are 
accompanied by cough, mucous production, and inflamma-
tion of the pulmonary tree. In nondiabetic adults, there was 
no difference in the pharmacokinetics or glucose response 
to inhaled insulin either during the acute or recovery phase 
of an upper respiratory tract infection.50 In addition, pul-
monary function tests (PFTs) following administration of 
inhaled insulin were unchanged in the same subjects. These 
observations suggest inhaled insulin is efficacious even in 
the clinical setting of acute upper respiratory infection. 
Comparable studies have not been performed in subjects 
recovering from lower respiratory tract infections such as 
pneumonia.
Asthma is a chronic disease characterized by inflamma-
tion and airway hyper-reactivity with periods of exacerbation 
and quiescence. In order for inhaled insulin to be recom-
mended in this population, it must not trigger bronchospasm, 
and it must be provide optimal blood sugar control during 
acute asthma exacerbations. In a study of non-diabetic sub-
jects with mild to moderate asthma, it was demonstrated 
that compared to healthy subjects, the overall exposure to 
insulin (AUC) was 34% to 41% less.51 The glucodynamic 
effects of inhaled insulin were comparable between healthy 
and subjects with mild asthma, while the ability of inhaled 
insulin to lower serum glucose was decreased in subjects with 
moderate asthma. This effect was ameliorated by pretreat-
ing subjects with a long-acting β-agonist to alleviate airway 
narrowing. There were no acute asthma exacerbations as a 
result of insulin inhalation.51
The prevalence of diabetes in patients with COPD 
is as high as 12%.52 This disease is categorized as being 
both restrictive (emphysema) and obstructive (chronic 
bronchitis) in its effects on pulmonary function. These 
complications may limit the ability of individuals to use the 
inhalation devices appropriately or may restrict the surface 
area available for insulin absorption across the alveolar 
membrane. Rave et al performed a randomized cross-over 
study comparing the responses to inhaled vs subcutaneous 
short-acting insulin in both healthy controls (nonsmokers) 
and individuals with COPD who had not smoked for lon-
ger than 6 months.53 They demonstrated that while inhaled 
insulin was well tolerated in those with chronic lung disease, 
serum levels of immunoreactive insulin following inhaled 
insulin administration were lower in individuals with COPD, 
particularly in those with chronic bronchitis compared to 
control subjects. The insulin effect in patients with COPD 
was 60% to 65% of the control subjects. Thus, for those with 
COPD, increased doses of inhaled insulin may be necessary 
to achieve the same degree of metabolic control. There 
were no acute effects on pulmonary function in response to 
insulin inhalation.53
Age and inhaled insulin
Both lung volumes and diffusion capacity change as a func-
tion of age.54 These changes can modulate both delivery of 
inhaled insulin to the distal airways, as well as absorption 
of the insulin across the alveolar epithelium. Henry et al 
demonstrated that in individuals with T2DM, increasing age 
(65 years) impacted the ability of inhaled insulin to lower 
glucose levels compared to a younger population (age 18 to 
45 years) while Cmax and AUC0–360 were not different between 
the two groups.55 These results indicate that, in older patients, 
an increased inhaled insulin dose may be required to achieve 
comparable diabetes control.
Adverse effects
The adverse effects of inhaled insulin are summarized in 
Table 2. There have been no adverse effects uniquely associ-
ated with a specific insulin formulation or delivery device.Vascular Health and Risk Management 2010:6 54
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Body weight
One concern with insulin therapy is that, with intensified 
protocols, weight tends to increase. This is particularly 
true for patients with T2DM, in whom excess weight gain 
contributes to worsening insulin resistance, with cor-
responding need for increased insulin doses. In studies 
enrolling patients with T1DM, there was either no change56 
or a trend towards less weight gain35,37 in those receiv-
ing inhaled insulin vs subcutaneous short-acting insulin 
analog. In a study of insulin-naïve patients with T2DM, 
inhaled insulin monotherapy or in conjunction with 2 oral 
agents resulted in a mean 2.7 kg weight gain compared to 
oral agent therapy.38 However, in individuals with T2DM 
previously receiving subcutaneous insulin therapy, there 
was no weight change in those treated with inhaled insulin 
vs those continued on subcutaneous insulin therapy.30 All 
individuals who transition to intensified diabetes care should 
be counseled about the risk of weight gain, regardless of 
the therapeutic regimen.
Hypoglycemia
Treatment strategies aimed at achieving euglycemia carry 
the risk of increased number and severity of hypoglycemic 
events.6 Inhaled insulin is associated similar rates of hypogly-
cemia when compared to subcutaneous insulin in both T1 and 
T2DM populations; no increase in severity of episodes was 
reported.30,35,56 In a study including subjects with T2DM on 
oral agent therapy alone prior to study entrance, the incidence 
of hypoglycemic events was greater in the cohorts receiv-
ing inhaled insulin compared to oral agents alone (66% to 
76% vs 8%).38 In addition, the rates of symptoms associated 
with hypoglycemia, including tremor, sweating, and head-
ache were higher in the inhaled insulin groups. However, 
the rate of severe hypoglycemic events, defined as an event 
requiring outside assistance, was not increased.38
Pulmonary function
Given that insulin therapy will be life-long for many 
diabetics, it is relevant to understand the effects that inhaled 
insulin has on lung function. There are hypothetical concerns 
about the toxicity of insulin particulates on the alveolar-
capillary network as well as the growth-promoting effects 
of insulin when it binds competitively, albeit at significantly 
lower potency, to insulin growth factor-1 receptors in the 
lung.22 Rosenstock et al demonstrated no changes in either 
forced expiratory volume at 1 second (FEV1) , total lung 
capacity, or carbon monoxide diffusion capacity (DLCO) in 
patients with T2DM receiving inhaled insulin for a period of 
12 weeks.38 A 2-year follow-up study in patients with T2DM 
treated with inhaled insulin as an adjunct to oral therapies 
demonstrated that there was a decrease in FEV1 and DLCO 
at 24 weeks of therapy that did not progress throughout 
the course of the study.57 Interestingly, the oral therapy 
group also showed similar declines during the course of the 
study, although the change in FEV1 was slightly greater in 
the inhaled insulin group. These findings are comparable 
to previous studies measuring the annual rate of change in 
FEV1 in a group of individuals with T2DM,58 suggesting 
that the declines do not reflect adverse effects of the drug, 
but, rather, represent the natural history of the disease with 
respect to lung function.
Short-term (6-month) studies in patients with T1DM have 
demonstrated that DLCO decreases by ∼0.75 to 1.2 mL/min/
mm Hg.34,35 Long-term study of the effects of inhaled insu-
lin on lung function in patients with T1DM is limited to a 
4-year extension trial combining patients with both T1 and 
T2DM. Annualized changes in FEV1 were -0.057 ± 0.004 
L/year in the inhaled insulin group and -0.071 ± 0.023 L/year 
in the control group, while DLCO changes were -0.376 ± 
0.067 mL/min/mmHg and -0.673 ± 0.423 mL/min/mmHg, 
respectively.59 Although these experiences suggest that 
Table 2 Side effects of inhaled insulin formulations
Side effect Degree of effecta Notes
Cough + Coincident with inhalation, decreased severity over time. Occasionally treatment limiting.
Change in FeV1 +/- FeV1 testing required by FDA prior to initiation of therapy.
Change in DLCO + Decline early in treatment then stable. Reversal of effect upon discontinuation of therapy.
insulin antibodies + increased titers compared to subcutaneous formulations. No correlation with pharmacologic effect.
Hypoglycemia +/- Less risk of severe hypoglycemia compared to subcutaneous insulin. increased risk in insulin naïve 
patients.
weight gain +/- Associated with addition of any insulin to therapeutic regimen in T2DM.   weight neutral to decrease 
in T1DM.
Notes: aDegree to which effect was observed when reported by investigators; +, effect consistently observed; +/-, effect inconsistently observed.
Abbreviations: DLCO, carbon monoxide diffusion capacity; FeV1, forced expiratory volume in 1 second.Vascular Health and Risk Management 2010:6 55
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inhaled insulin is safe with respect to lung function, when 
Exubera® was on the market, it was recommended that all 
patients have FEV1 tested at baseline, after 6 months of 
therapy, and annually while taking the drug. For individu-
als with FEV1  70% predicted or a decline 20%, it was 
recommended that the drug be discontinued. Longer-term 
studies will help to determine whether the effects of inhaled 
insulin on pulmonary function have clinical repercussions.
Mild to moderate cough occurs more frequently in indi-
viduals receiving inhaled insulin. Coughing episodes were 
usually reported coincident with insulin inhalation.23 How-
ever, both the rate and severity of this effect decreased over 
time in studies reporting this outcome.34,35,38 No differences in 
cough rates were observed in subjects using Technosphere® 
inhaled insulin vs Technosphere® placebo powder.23 In 
addition, cough was not a significant contributor to subject 
withdrawal from clinical studies.
insulin antibodies
The delivery of insulin whether subcutaneously, intraperito-
neally, or by inhalation leads to the formation of circulating 
insulin immunoglobulins.60–62 High circulating levels of insu-
lin antibodies may disrupt glycemic control by 2 mechanisms. 
First, the antibodies may bind to the insulin blocking its action 
with resulting hyperglycemia.63,64 Secondly, the insulin may 
then be released from the antibody complex, with inappropri-
ate insulin action (discordant with carbohydrate intake) and 
delayed hypoglycemia.65,66 In rare cases, true insulin allergies 
may develop.62
The experience with inhaled insulin has not unearthed 
these concerns. In patients with both T1DM and T2DM, 
levels of insulin antibodies were measured following 
the introduction and use of inhaled insulin. Individuals 
with T1DM using inhaled insulin had a 22% increase in 
the median percentage antibody binding compared to those 
treated with CSII therapy.67 For patients with T2DM, the 
use of inhaled insulin led to the development of insulin 
antibodies. The peak levels were significantly lower than 
those observed in patients with T1DM, and peak antibody 
levels were reached within 6 to 12 months of inhaled insulin 
exposure. Insulin antibody levels increased in all groups 
treated with inhaled insulin; there was no association of 
antibodies with hypo/hyperglycemia, deterioration of meta-
bolic control, allergic reactions, or changes in pulmonary 
function testing. Thus, while the delivery of insulin to the 
pulmonary system induces immune responses, these have 
not been demonstrated to decrease the effectiveness of 
inhaled insulin over time.68
Quality of life and adherence  
to therapy
One of the proposed benefits to inhaled insulin therapy is that, 
in contrast to injections, it will be accepted more readily by 
patients when insulin therapy must be intensified or when 
oral therapy is failing to achieve glycemic goals. Freemantle 
et al demonstrated that the availability of inhaled insulin as 
a hypothetical treatment option increases the likelihood that 
patients with poorly controlled T2DM will accept the addi-
tion of insulin to their therapeutic regimen.69 Alternatively, 
Bergenstal et al addressed the question of whether having the 
opportunity to choose AIR® insulin increased the likelihood 
that individuals with poorly controlled T2DM would choose 
any insulin therapy.70 In this study, subjects were random-
ized to receive counseling on therapeutic options to inten-
sify diabetes management that either excluded or included 
inhaled insulin. The study determined that the availability of 
inhaled insulin did not increase the likelihood that individuals 
would add insulin to their treatment regimen. In addition, both 
groups had a comparable improvement in HbA1c regardless of 
whether they added inhaled or subcutaneous insulin.70 Finally, 
patients with T1DM who received Exubera® reported higher 
overall satisfaction scores and quality of life scores compared 
to those receiving subcutaneous therapy.35 Rosenstock et al 
reported that, following a 12-week randomized controlled 
trial comparing inhaled and subcutaneous insulin, 85% of 
patients randomized to inhaled insulin elected to continue the 
drug, and 75% of those randomized to subcutaneous therapy 
elected to switch to inhaled insulin. In addition, overall 
satisfaction with inhaled insulin therapy was sustained for 
1 year of therapy and impacted psychological well-being in 
a positive manner.42 This is an important finding given that 
the glycemic control in these patients was comparable to that 
of subcutaneous insulin and did not deteriorate throughout 
the extension phase of the study,42 suggesting that adherence 
to inhaled insulin therapy remained high.
Adherence is the measure that a patient is taking medi-
cations as prescribed by their provider. Rates of adherence 
are lowest in chronic diseases, and decline with increases in 
daily dosing.71 Claxton et al showed that with four times/day 
medication schedule, the rate of adherence was less than 
50%.72 Individuals with diabetes often have multiple medi-
cal problems, necessitating polypharmacy with complicated 
dosing schedules. Therefore, any delivery system improving 
adherence in the diabetic population would be welcome. 
Measuring adherence to subcutaneous insulin therapy via 
syringe is difficult; proxy outcomes are number of prescrip-
tions filled, vials of insulin used, and difference in HbA1c Vascular Health and Risk Management 2010:6 56
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following initiation of therapy. The AERx® system records 
the date and time of each insulin administration as well as the 
adequacy of the inhalation technique. Rates of adherence to 
preprandial insulin administration were as high as 95% in a 
group of patients with T2DM using the AERx® system, and 
97% of patients received less than 5 inadequate doses dur-
ing the treatment period studied.73 Thus, this inhaled insulin 
system may serve as a useful tool to aid in acceptance of 
insulin and improvement of glycemic control.
Cost of inhaled insulin
The cost of inhaled insulin is significantly higher than that 
of subcutaneous insulin since more drug must be inhaled 
in order to achieve comparable glycemic control. However, 
a substantial driving force for the development of inhaled 
insulin has focused on the concept that availability of alter-
nate insulin delivery systems will increase the likelihood that 
those with diabetes will adhere to their treatment regimens. 
In particular, those with T2DM may be more willing to 
start insulin when inhaled insulin is available as an option.69 
Adherence and intensified diabetes care would translate 
into improved diabetes outcomes, particularly for decreased 
rates of micro- and macrovascular complications. Thus, the 
cost-effectiveness of inhaled insulin for quality of life and 
downstream clinical benefits can be considered when evaluat-
ing the economics of inhaled insulin.
Black et al performed an extensive analysis of the cost 
and cost-effectiveness of Exubera® in patients with T2DM.74 
They determined that the addition of Exubera® to a regimen 
which included 2 oral agents was US$1669/year more than 
adding basal glargine. Using a model to calculate cost-
effectiveness assuming that inhaled insulin would improve 
quality of life and glycemic control over the lifetime of 
the patient, the authors determined that, while quality of 
life cost-savings of US$110 to US$220 per patient might 
be realized over 20 years of therapy, this was significantly 
outweighed by the excess cost compared to basal subcutane-
ous therapy – US$14,000 to US$20,700. Given that inhaled 
insulin is not superior to subcutaneous therapy with respect 
to glycemic control, there would have to be additional direct 
patient benefits to improve cost-effectiveness. These analyses 
will be considered by third party payers when making deci-
sions on reimbursement for inhaled insulin.
Conclusions
Several important issues remain with respect to the likelihood 
that inhaled insulin will be used clinically in the future. The 
first is the significant impact that the launch and subsequent 
withdrawal of Exubera® from the market had on the continued 
study and development of competing inhaled insulin devices. 
The second major development is the report from Pfizer that 
there is an increased incidence of lung cancer among former 
smokers who were treated with Exubera®.49 As a consequence 
of this revelation, it is likely that the FDA will limit the use 
of inhaled insulin to individuals who have never smoked and 
require extensive postmarketing studies to address issues 
related to carcinogenicity risk. Finally, with the continued 
development of devices that have improved the ability to 
deliver subcutaneous insulin, including insulin pumps and 
insulin pens, the niche in the diabetes market which inhaled 
insulin is likely to occupy may be limited. Although the 
concept of inhaled insulin is attractive, the availability of 
subcutaneous insulin regimens that provide intensive diabetes 
care and the concern about pulmonary function and health 
will significantly affect future development in this area.
In conclusion, inhaled insulin is a novel route of insulin 
administration which has the potential to become a thera-
peutic option in the treatment of both T1DM and T2DM. 
Overall, clinical trials have demonstrated that inhaled insulin 
is noninferior to subcutaneous insulin for improving glyce-
mic control. In addition, inhaled insulin serves as relevant 
adjuvant therapy in individuals with T2DM suboptimally 
controlled on oral therapy. The most notable advantage of 
inhaled insulin over subcutaneous insulin therapy is that it is 
well accepted by patients and improves overall satisfaction 
scores. Thus, availability of inhaled insulin may translate to 
improved diabetes control and decrease the risk of long-term 
diabetes complications.
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